Latest stories on ACXP
Acurx Pharmaceuticals, Inc. (ACXP) files 8-K
SEC 8-K50 · neutralgeneral
Acurx Pharmaceuticals, Inc. (ACXP) files 8-K
SEC 8-K50 · neutralgeneral
Acurx Pharmaceuticals Takes Its Antibiotics Story Global Through a 12-Month Series with New to The Street
Business Insider56 · neutralproduct/pr
Acurx outlines 20-patient PATHFINDER start in Q4 as FDA stays open to a single Phase III ASPIRE for ibezapolstat
Seeking Alpha58 · neutralproduct/pr
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Acurx Pharmaceuticals GAAP EPS of -$0.53 misses by $0.19
Seeking Alpha34 · bearishearnings
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update
PR Newswire50 · neutralearnings
Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics
PR Newswire67 · bullishproduct/pr
FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection
PR Newswire67 · bullishproduct/pr
Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat
Morningstar73 · bullishproduct/pr
Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
PR Newswire50 · neutralearnings